GIHN || Clinical

Obeticholic acid shows promise in primary biliary cirrhosis

Posted on: 15/04/2014 - 15:35

LONDON – Obeticholic acid significantly reduced key liver enzyme and bilirubin levels in patients with primary biliary cirrhosis in a phase III trial. Results of <link...

Field of Interest: Gastroentero...

Type: News Item

Outcomes linked to distance from liver transplant center

Posted on: 25/03/2014 - 20:00

Eligible patients who live farther away from a liver transplant center are less likely to be put on a waiting list, less likely to receive a transplant, and more likely to die within 5 years than are...

Field of Interest: Oncology

Type: News Item

Outcomes linked to distance from liver transplant center

Posted on: 25/03/2014 - 20:00

Field of Interest: Gastroentero...

Type: News Item

Immunosuppressive therapy ups risk for skin cancers

Posted on: 23/01/2014 - 14:35

HOLLYWOOD, FLA. – Current and previous use of thiopurines, biologics, and combination therapies are all independent risk factors for skin cancer, according to expert analysis given at a conference on...

Field of Interest: Gastroentero...

Type: News Item

Trial immunosuppressive therapy benefits outweigh long-term lymphoma risks in IBD

Posted on: 22/01/2014 - 18:40

HOLLYWOOD, FLA. – The benefits of short-term trial immunosuppressive therapy outweigh the risks in inflammatory bowel disease, but certain patient populations require more vigilance than others, Dr....

Field of Interest: Gastroentero...

Type: News Item

Expanded genetic testing better predicts panitumumab plus chemo response

Posted on: 15/01/2014 - 19:50

SAN FRANCISCO – Patients with metastatic colorectal cancer should be broadly tested for RAS mutations before being treated with panitumumab, according to new data from a <link...

Field of Interest: Gastroentero...

Type: News Item

FDA advisers back vedolizumab approval to treat moderate to severe inflammatory bowel disease

Posted on: 18/12/2013 - 17:10

SILVER SPRING, MD. – The benefits of vedolizumab, an integrin antagonist, outweigh the potential for progressive multifocal encephalopathy and other possible risks as a treatment for moderate to...

Field of Interest: Gastroentero...

Type: News Item

Telaprevir label changes include switch to twice-daily dosing

Posted on: 13/12/2013 - 17:30

The label of the hepatitis C antiviral drug telaprevir has been changed to include new dosing recommendations and contraindications, described in a "Dear Healthcare Professional" letter...

Field of Interest: Gastroentero...

Type: News Item

Newsletters

Stay informed on our latest news!

You are here

Newsletters

Latest Newsletters